fda compounding glp-1 crackdown news today is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA Escalates Enforcement Against Compounded

J., and Martin, S

Albeit with some alarming side effects, including nausea, vomiting, diarrhea, abdominal pain, rapid heartbeat, vision changes, fainting or dizziness, and more

Always consult a qualified healthcare provider with any medical questions or concerns.

What they found (summary): Amylin is a critical partner of insulin in metabolism, the loss of amylin in T2DM is as significant as the loss of insulin The AMY1 receptor in the area postrema is the primary target for the appetite effect Amyloid aggregation is the main problem with native amylin, proline substitutions (the Pramlintide strategy) are essential The half-life of native amylin is only 13 minutes, that is why lipidated analogs like Cagrilintide are necessary Perspective: amylin + GLP-1 combinations are the natural evolution of metabolic pharmacotherapy Why it matters: This is the reference article for amylin pharmacology